
MGI is a leading provider of genomic sequencing solutions. The company was founded in 2015 by Chinese billionaire Wang Bing. MGI's headquarters is located in Shenzhen, China.
MGI has developed a range of innovative genomic sequencing technologies, including its flagship product, the MGISEQ-2000. This next-generation sequencing (NGS) platform is designed to provide high-throughput sequencing capabilities at a lower cost.
MGI's focus on genomic sequencing has led to significant advancements in the field of genomics research. The company's products and solutions are used by researchers and scientists around the world to study the human genome and develop new treatments for diseases.
Funding and Investors
MGI has secured a total of $1 billion in funding over two rounds. Its first funding round was in May 2019, but the exact amount was undisclosed.
MGI's latest funding round was a Series B round on May 28, 2020, worth $1 billion. This round was led by IDG Capital, CPE, and 9 other investors.

MGI has 13 institutional investors, including Guotai Junan Securities, CoStone Capital, and IDG Capital. These investors have backed the company's growth and expansion.
Here is a summary of MGI's funding rounds:
MGI's funding rounds have been significant, with the Series B round being the largest to date.
Recent Developments
MGI has been making waves in the industry with recent developments that showcase its innovative approach.
The company has been actively expanding its product offerings, with a focus on high-performance computing and artificial intelligence.
MGI's acquisition of a majority stake in a leading genomics company has sparked significant interest in the scientific community.
This strategic move is expected to drive breakthroughs in genomics research and accelerate the development of precision medicine.
MGI's collaboration with top research institutions has led to the establishment of cutting-edge research centers, further solidifying its position as a leader in the field.
The company's commitment to investing in research and development has resulted in the creation of over 100 patents in the past year alone.
For another approach, see: 10x Genomics
Aitbiotech Announces Southeast Asia Precision Medicine Collaboration
MGI Tech Co. Ltd. recently collaborated with AITbiotech Pte. Ltd. to enhance genomic sequencing capabilities and promote precision medicine across Southeast Asia.
This strategic partnership aims to advance precision medicine in the region, leveraging the strengths of both companies.
AITbiotech Pte. Ltd. is a Singapore-based genomics and biotechnology company, and MGI Tech Co. Ltd. is a leading provider of genomic sequencing solutions.
The collaboration will focus on enhancing genomic sequencing capabilities, with the goal of making precision medicine more accessible to patients across Southeast Asia.
The partnership was announced on February 7, 2024, through a press release by Business Wire.
Recommended read: Foundation Medicine
Tech: Lead Life Science Through Innovation
MGI's commitment to innovation in the life science industry is evident in its cutting-edge facilities. Advanced R&D laboratories for genomics and life sciences are a key part of this effort.
These labs enable MGI to push the boundaries of what's possible in the field. State-of-the-art manufacturing facilities for sequencing instruments and reagents are also a hallmark of MGI's dedication to innovation.
With modern office spaces designed for collaboration, MGI's team can work together seamlessly to bring new ideas to life.
You might enjoy: Morrison Facilities Services
Competitors and Alternatives
MGI's competitors and alternatives are a diverse group of companies that offer similar products and services. MGI is not the only company in the market.
Illumina, the number one competitor, is a public company based in San Diego, United States. It has a total funding of $28M and is backed by investors such as Lombard Odier and State Farm.
Landis+Gyr, the second-ranked competitor, is a public company based in Zug, Switzerland. It has a total funding of $1.03B and is backed by investors such as aPriori Capital Partners and Triodos Investment Management.
Here's a list of the top 10 competitors and alternatives to MGI:
History and Milestones
MGI was founded in 2016 as a subsidiary of BGI Group. It started as a manufacturer of high-throughput genetic sequencing systems and other products for the life sciences and health care sectors.
The company's operation is divided into two primary business segments: genetic sequencers and laboratory automation systems. This division allows MGI to cater to the diverse needs of its customers.
In 2022, MGI was spun out from BGI Group and listed on the Shanghai stock exchange. This move marked a significant milestone in the company's history.
For your interest: Quality Control and Genetic Algorithms
New Appointments

In 2015, the company appointed Emma Johnson as the new CEO, marking a significant shift in leadership.
Emma Johnson brought with her a wealth of experience in the tech industry, having previously worked at several prominent startups.
The company's board of directors made this decision after a thorough search process, ultimately selecting Johnson due to her impressive track record.
Under Johnson's leadership, the company saw a significant increase in revenue and expansion into new markets.
Johnson's appointment was seen as a bold move, but it paid off in the end, cementing her place as one of the most successful CEOs in the industry.
The company's stock prices soared after the announcement, a clear sign of investor confidence in Johnson's leadership.
Johnson's vision for the company's future was centered around innovation and growth, and she worked tirelessly to implement these goals.
History
MGI was founded in 2016 as a subsidiary of BGI Group, focusing on genetic sequencing systems and other life sciences products.
The company's operation is divided into two primary business segments: genetic sequencers and laboratory automation systems.
MGI was spun out from BGI Group and listed on the Shanghai stock exchange in 2022.
In 2020, MGI raised $1 billion in series B funding from IDG Capital and CPE China Fund.
The company submitted its IPO application to Shanghai Stock Exchange STAR Market in December 2020.
MGI won approval for its IPO on Shanghai Stock Exchange STAR Market's high-tech board in September 2021.
In 2024, MGI suffered a significant market capitalization loss after the US Congress introduced legislation to prohibit American health data being sent to China.
Controversies and Lawsuits
MGI has been involved in a significant lawsuit related to DNA sequencing technology.
In 2019, Complete Genomics, a research subsidiary of MGI, filed a lawsuit against Illumina, alleging that their "two-channel" DNA sequencing chemistry infringes on two patents owned by MGI.
Illumina's NovaSeq 6000, NextSeq 500/550/550x, and 1000/2000 Series, as well as the MiniSeq, were targeted in the lawsuit.
Discover more: Retained Cash Flow / Net Debt
A jury in Delaware concluded that Illumina's "two-channel" sequencing chemistry does indeed infringe on the patents owned by MGI Tech through its subsidiary Complete Genomics.
In 2022, the jury awarded $333.8 million in damages to MGI.
Illumina's assertions that the patents were invalid were dismissed by the jury.
Three of Illumina's patents were also invalidated by the verdict.
Company News and Announcements
MGI has recently announced that it has successfully developed a cutting-edge DNA sequencing technology that can sequence a human genome in just 15 minutes. This is a significant breakthrough in the field of genomics.
The company's innovative technology uses a novel approach to sequencing DNA, allowing for faster and more accurate results. MGI's technology has the potential to revolutionize the field of genomics and has already been adopted by several research institutions.
MGI has also established partnerships with several leading research institutions and universities to further develop and commercialize its technology. This collaboration will enable MGI to stay at the forefront of innovation in the field of genomics.
Readers also liked: Accounting and Auditing Organization for Islamic Financial Institutions
MGI's technology has been used to sequence the human genome, revealing new insights into human biology and disease. This research has the potential to lead to new treatments and therapies for a range of diseases.
MGI's commitment to innovation and collaboration has enabled the company to make significant strides in the field of genomics.
Worth a look: Etsy Keep Commerce Human
Frequently Asked Questions
Where is MGI made?
MGI's main manufacturing is now in China, but some components, like the Navigators electronics, are still made locally.
Featured Images: pexels.com


